Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
11.41
-0.76 (-6.24%)
Dec 20, 2024, 4:00 PM EST - Market closed
Benitec Biopharma Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Operating Revenue | - | - | 0.08 | 0.07 | 0.06 | 0.1 | Upgrade
|
| Revenue | - | - | 0.08 | 0.07 | 0.06 | 0.1 | Upgrade
|
| Revenue Growth (YoY) | - | - | 2.74% | 23.73% | -42.16% | -99.16% | Upgrade
|
| Cost of Revenue | -0 | -0.11 | - | 0.01 | 0.12 | -0.19 | Upgrade
|
| Gross Profit | 0 | 0.11 | 0.08 | 0.06 | -0.06 | 0.29 | Upgrade
|
| Selling, General & Admin | 7.64 | 6.99 | 6.38 | 6.65 | 6.51 | 5.57 | Upgrade
|
| Research & Development | 14.77 | 15.61 | 12.77 | 11.27 | 7.02 | 3 | Upgrade
|
| Operating Expenses | 22.41 | 22.6 | 19.16 | 17.92 | 13.53 | 8.57 | Upgrade
|
| Operating Income | -22.41 | -22.49 | -19.08 | -17.85 | -13.6 | -8.28 | Upgrade
|
| Interest Expense | - | - | -0.03 | -0.03 | -0.01 | - | Upgrade
|
| Interest & Investment Income | 1.51 | 0.9 | - | - | - | 0.06 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.19 | 0.04 | -0.42 | -0.23 | -0.33 | -0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.15 | -0.2 | -0.03 | -0.08 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -20.86 | -21.75 | -19.56 | -18.2 | -13.94 | -8.31 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0 | -0 | -0 | -0.01 | 0.02 | -0 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.04 | 0.03 | Upgrade
|
| Pretax Income | -20.86 | -21.75 | -19.56 | -18.21 | -13.88 | -8.27 | Upgrade
|
| Net Income | -20.86 | -21.75 | -19.56 | -18.21 | -13.88 | -8.27 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | 0.62 | - | - | - | - | Upgrade
|
| Net Income to Common | -20.86 | -22.37 | -19.56 | -18.21 | -13.88 | -8.27 | Upgrade
|
| Shares Outstanding (Basic) | 6 | 4 | 1 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 6 | 4 | 1 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 250.17% | 192.98% | 188.30% | 90.24% | 320.63% | 19.19% | Upgrade
|
| EPS (Basic) | -3.37 | -5.51 | -14.12 | -37.88 | -54.94 | -137.74 | Upgrade
|
| EPS (Diluted) | -3.37 | -5.51 | -14.12 | -37.88 | -54.94 | -137.74 | Upgrade
|
| Free Cash Flow | -19.59 | -19.58 | -18.01 | -15.91 | -13.05 | -7.63 | Upgrade
|
| Free Cash Flow Per Share | -3.17 | -4.82 | -13.00 | -33.10 | -51.66 | -127.02 | Upgrade
|
| Gross Margin | - | - | 100.00% | 87.67% | -108.47% | 281.37% | Upgrade
|
| Operating Margin | - | - | -25441.33% | -24457.53% | -23044.07% | -8118.63% | Upgrade
|
| Profit Margin | - | - | -26082.67% | -24942.47% | -23528.81% | -8111.76% | Upgrade
|
| Free Cash Flow Margin | - | - | -24017.33% | -21797.26% | -22123.73% | -7480.39% | Upgrade
|
| EBITDA | -22.31 | -22.4 | -18.95 | -17.69 | -13.37 | -8.09 | Upgrade
|
| D&A For EBITDA | 0.09 | 0.09 | 0.14 | 0.17 | 0.23 | 0.19 | Upgrade
|
| EBIT | -22.41 | -22.49 | -19.08 | -17.85 | -13.6 | -8.28 | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 0.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.